CTA

HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, FACC, Coronary artery disease, Risk, Patient, Atherosclerosis, CTA, Journal, Artificial intelligence, FFR, AI, Fierce, Safety, Trailblazer, CAD, Medical device

MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that 10-year follow-up data from its DISCOVER-FLOW study were published in the Journal of Cardiovascular Computed Tomography.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that 10-year follow-up data from its DISCOVER-FLOW study were published in the Journal of Cardiovascular Computed Tomography .
  • The company has spent the last decade working with clinicians to improve CAD diagnosis, making significant progress validated by high quality clinical evidence.
  • HeartFlow’s approach is centered around scientific rigor with peer-reviewed publications to provide confidence and certainty to clinicians and the patients they serve.
  • Together, this comprehensive solution offers valuable data not currently available with other non-invasive diagnostic tools or CTA-based AI analyses.

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Retrieved on: 
Tuesday, March 12, 2024
Human, Obesity, Disease, Diabetes, Weight loss, CTA, Mouse, T2D, Therapy, DSM-IV codes, Pharmaceutical industry

BURLINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform. RJVA-001 is the Company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.

Key Points: 
  • Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control.
  • These results with a native, short half-life human GLP-1 sequence to be used in RJVA-001 build upon earlier results with a prototype transgene GLP-1 analogue.
  • RJVA-001 is the Company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.
  • The Company has reached alignment with European regulators on the use of this efficacy model to support the submission of a Clinical Trial Application (CTA) in Europe.

Ai For Alpha Unveils New "Global Macro Decoding" Strategy

Retrieved on: 
Wednesday, April 3, 2024
Data Analytics, Fintech, Professional Services, Finance, Alpha, CTA, CTAS, Business development, Global macro, AI, Marketing

Ai for Alpha , a pioneering fintech firm specializing in leveraging AI for sophisticated investment strategies, today announced the launch of its "Global Macro Decoding" strategy.

Key Points: 
  • Ai for Alpha , a pioneering fintech firm specializing in leveraging AI for sophisticated investment strategies, today announced the launch of its "Global Macro Decoding" strategy.
  • Beatrice Guez, CEO of Ai for Alpha, described this innovative strategy as a significant enhancement to the company's suite of decoding replication strategies.
  • "It mirrors the industry's leading Global Macro Hedge fund Strategies, skillfully navigating macroeconomic dynamics in equities, credit, sovereign bonds, commodities, and currencies," Guez explained.
  • Key Ai Global Macro Decoding statistics: achieving a high correlation to the Global Macro Benchmark and superior risk-adjusted return.

Kazakhstan Startup CerebraAI Relocates Headquarters to Silicon Valley to Address Severe Emergency Care Diagnostics Gap through Novel Generative AI Medical Imaging Approach

Retrieved on: 
Tuesday, April 2, 2024
Software, General Health, Health, Artificial Intelligence, Medical Devices, Data Management, Health Technology, Technology, Stroke, Algorithm, MRI, Magnetic resonance imaging, NCCT, Physician, Patient, Silk Road, CTA, Hospital, AI, Radiology, Computed tomography angiography, Death, Hope, Eye, Silicon, Ecosystem, Silk, Multimedia, CTP, Map, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240402257293/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240402257293/en/
    Stroke is a leading cause of death and long-term disability in the U.S. and globally.
  • Following algorithm training and extensive studies in Kazakhstan, with over 130,000 patients analyzed, development is currently underway to introduce CerebraAI’s medical imaging software to the U.S. market.
  • “CerebraAI is one of the first deep tech AI startups in Kazakhstan and they are making a meaningful difference in serving humanity with their novel approach to acute ischemic stroke detection.
  • They are pioneering a new future in emergency care medical imaging diagnostics.”

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5

Retrieved on: 
Tuesday, March 26, 2024
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, CNRS, Neurology, AAV, Motivation, Environment, Scientific method, Patient, CTA, DSM-IV codes, Biomarker, Research, ANSM, University, EMA, European Medicines Agency, Clinical trial, Therapy, Muscular dystrophy, Safety, Pathology, Weakness, Cardiomyopathy, Pharmaceutical industry

This authorization was first granted by the Italian Medicines Agency (AIFA), then by the French Medicines Agency (ANSM).

Key Points: 
  • This authorization was first granted by the Italian Medicines Agency (AIFA), then by the French Medicines Agency (ANSM).
  • Giacomo Comi, Full Professor of Neurology at the University of Milan (Italy), and principal investigator of this trial.
  • ATA-200, a gene therapy candidate for LGMD2C/R5, delivers a normal copy of the gene for production of γ-sarcoglycan protein.
  • In addition to its LGMD2C/R5 gene therapy, Atamyo is developing a clinical trial with ATA-100 gene therapy for LGMD2I/R9, related to deficiencies in FKRP; and is in IND-enabling studies for LGMD2A/R1, related to deficiencies in calpain protein.

Wolters Kluwer expert provides insights on Beneficial Ownership reporting requirements for trusts

Retrieved on: 
Thursday, March 21, 2024
Legal, Finance, Consulting, Banking, Accounting, Professional Services, Small Business, Asset Management, Other Professional Services, Beneficial ownership, BOI, Wolters Kluwer, CTA, CT Corporation, Interview, Financial Crimes Enforcement Network, Small business, Trustee, Hearing

“The eligibility of trusts for Beneficial Ownership Information reporting is complicated due to the expansive nature of them,” explains May.

Key Points: 
  • “The eligibility of trusts for Beneficial Ownership Information reporting is complicated due to the expansive nature of them,” explains May.
  • Wolters Kluwer has recently published a white paper clarifying the circumstances under which trusts and the reporting companies they manage must conform to the new BOI reporting requirements.
  • Reporters wishing to arrange an interview on with Wolters Kluwer experts on this topic are invited to contact David Feider , Associate Director, External Communications, Wolters Kluwer FCC.
  • More information on navigating the new beneficial ownership reporting requirements is available on the Wolters Kluwer resource page, “ Beneficial Ownership Information Compliance from CT Corporation .”
    For more information about Wolters Kluwer, please visit: www.wolterskluwer.com .

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

Retrieved on: 
Tuesday, March 19, 2024
FDA, Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Precision BioSciences, Conference, Gene editing, Cell, CTA, Mitochondrial myopathy, Mitochondrion, DNA, Smith, Doctor of Philosophy, IND, CRISPR, Heteroplasmy, PMM, Vaccine

These data are being presented at the Mitochondrial Medicine – Therapeutic Development Annual Conference, being held from March 18-20, 2024 in Hinxton, UK.

Key Points: 
  • These data are being presented at the Mitochondrial Medicine – Therapeutic Development Annual Conference, being held from March 18-20, 2024 in Hinxton, UK.
  • “Today’s data from our PBGENE-PMM program further validate our work with ARCUS and continue to demonstrate its ability to make precise edits while avoiding off-target activity,” said Jeff Smith, PhD, Chief Research Officer of Precision BioSciences.
  • PBGENE-PMM is designed to eliminate mutant mitochondrial DNA leaving normal functioning wild-type mitochondrial DNA intact to repopulate the cell, resulting in a shift in heteroplasmy and improvement in mitochondrial function.”
    Smith continued, “Additionally, ARCUS can cross mitochondrial membranes in order to access the mitochondrial DNA.
  • Together, these data support the development of PBGENE-PMM as a single-treatment, in vivo gene editing therapeutic for m.3243-associated primary mitochondrial myopathy.

Wolters Kluwer Beneficial Ownership Platform Wins 2024 FinTech Breakthrough Award

Retrieved on: 
Thursday, March 14, 2024
Legal, Software, Consulting, Small Business, Accounting, Professional Services, Technology, Fintech, Digital banking, Environment, BOI, Wolters Kluwer, Risk, CTA, Regulatory technology, Small business, Cryptocurrency

Wolters Kluwer , a global leader in professional information, software solutions, and services, has been recognized for product excellence in the FinTech Breakthrough Awards’ Fraud Prevention Innovation category for development of its Beneficial Ownership Platform .

Key Points: 
  • Wolters Kluwer , a global leader in professional information, software solutions, and services, has been recognized for product excellence in the FinTech Breakthrough Awards’ Fraud Prevention Innovation category for development of its Beneficial Ownership Platform .
  • Wolters Kluwer’s expert solution aims at helping the nearly 33 million businesses impacted by the beneficial ownership reporting rule under the U.S. Corporate Transparency Act (CTA).
  • “We were first to announce to the market the launch of a beneficial ownership reporting solution on January 2nd, 2024.
  • “We appreciate the FinTech Breakthrough team for recognizing our important product innovations.”
    Wolters Kluwer’s Beneficial Ownership Platform supports compliant Beneficial Ownership Information (BOI) filing, providing a secure, streamlined workflow to simplify filing and compliance for both single-entity as well as multiple-entity filers.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.